The India biosimilar market size was valued at INR 2.20 billion in 2025, driven by the rising prevalence of chronic diseases across the region. The market is expected to grow at a CAGR of 25.20% during the forecast period of 2025-2034, with values likely to rise from INR 2.8 billion in 2025 to INR 16.6 billion by 2034.
Get a Free Sample Report with a Table of Contents: https://www.expertmarketresearch.com/reports/india-biosimilar-market/requestsample
India Biosimilar Market Overview
Biosimilars are biologic medical products highly similar to approved reference drugs, offering a cost-effective alternative. India has emerged as a global leader in biosimilar manufacturing due to its robust pharmaceutical infrastructure and cost-effective production capabilities. The rising burden of chronic diseases such as cancer, diabetes, and autoimmune disorders has significantly increased the demand for biosimilars. Government support, strategic collaborations, and increased focus on innovation further strengthen India’s position in the biosimilar market.
India Biosimilar Market Dynamics
1. Market Drivers
- Rising Prevalence of Chronic Diseases: The increasing burden of non-communicable diseases drives demand for affordable treatment options.
- Cost-Effectiveness of Biosimilars: Biosimilars are a cost-effective alternative to expensive biologics, making them accessible to a larger population.
- Favourable Regulatory Framework: The Indian government has implemented policies to streamline biosimilar approvals, encouraging market growth.
- Expanding Biopharma Industry: India’s robust pharmaceutical sector and expertise in biologics manufacturing contribute to the biosimilar market’s development.
2. Market Challenges
- Stringent Regulatory Requirements: Developing biosimilars requires compliance with complex regulatory standards, increasing development time and costs.
- Market Competition: The presence of numerous players intensifies competition, affecting pricing strategies.
- Awareness and Acceptance: Limited awareness among healthcare providers and patients about biosimilars may hinder market penetration.
3. Opportunities
- Emerging Therapeutic Areas: Expanding the use of biosimilars in oncology, immunology, and endocrinology creates growth potential.
- Global Market Expansion: Indian biosimilar manufacturers have opportunities to penetrate international markets.
- Advancements in Biomanufacturing: Innovations in production technologies improve biosimilar quality and reduce costs.
External India Biosimilar Market Trend
- Growing Investment in R&D: Indian companies are investing heavily in biosimilar research to enhance product portfolios.
- Collaborations and Partnerships: Collaborations between Indian and global pharmaceutical companies boost biosimilar development and distribution.
- Focus on Oncology Biosimilars: Increased prevalence of cancer has led to a growing demand for oncology biosimilars.
- Adoption of Digital Technologies: Digital tools and AI are being utilised to optimise biosimilar development and manufacturing processes.
India Biosimilar Market Segmentation
1. By Product Type
- Monoclonal Antibodies (mAbs): Widely used for cancer, autoimmune disorders, and inflammatory diseases.
- Insulin Biosimilars: Gaining popularity for diabetes management.
- Erythropoietin: Used for anaemia associated with chronic kidney disease or chemotherapy.
- Other Biosimilars: Including growth hormones and interferons.
2. By Application
- Oncology: The largest segment, driven by the rising prevalence of cancer.
- Autoimmune Diseases: Increasing cases of rheumatoid arthritis and inflammatory bowel disease fuel this segment.
- Diabetes: High demand for insulin biosimilars drives growth in this segment.
- Others: Applications in ophthalmology, cardiovascular diseases, and infectious diseases.
3. By Distribution Channel
- Hospital Pharmacies: Major distribution channel due to the high reliance on institutional care.
- Retail Pharmacies: Growing importance in urban and semi-urban areas.
- Online Pharmacies: Emerging as a convenient channel for biosimilar access.
4. By Region
- North India: Leads the market due to advanced healthcare infrastructure.
- South India: Known for strong pharmaceutical manufacturing hubs.
- Other Regions: Include East and West India with growing healthcare investments.
India Biosimilar Market Growth
The market’s rapid growth is attributed to increased healthcare spending, improved accessibility to biosimilars, and rising public and private sector investments. India’s biosimilar industry is poised to grow exponentially, backed by its expertise in biopharmaceuticals and an expanding global footprint.
Read Full Report with Table of Contents: https://www.expertmarketresearch.com/reports/india-biosimilar-market
Recent Developments in the India Biosimilar Market
- New Product Launches: Introduction of novel biosimilars targeting oncology and autoimmune diseases.
- Strategic Alliances: Collaborations between domestic and international firms enhance market reach.
- Regulatory Advancements: Streamlined approval processes facilitate quicker biosimilar launches.
- Digital Innovations: Integration of AI and machine learning to optimise development pipelines.
India Biosimilar Market Scope
The scope of the biosimilar market in India extends across multiple therapeutic areas, catering to domestic and international demand. The market encompasses a wide range of products and services, from development to distribution, with significant potential for innovation and expansion.
India Biosimilar Market Analysis
India’s biosimilar market is a dynamic and rapidly evolving segment of the healthcare industry. The country’s competitive edge lies in its cost-effective manufacturing capabilities, skilled workforce, and supportive government policies. The growth of biosimilars in India not only caters to the domestic market but also strengthens its position in the global pharmaceutical landscape.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the biosimilar market:
- Supply Chain Disruptions: Challenges in raw material procurement and logistics temporarily affected production.
- Increased Focus on Biologics: The pandemic highlighted the importance of biopharmaceuticals, boosting biosimilar investments.
- Adoption of Digital Solutions: Remote monitoring and digital health tools accelerated biosimilar development and adoption.
Key Players in the India Biosimilar Market
1. Pfizer Inc.
Pfizer is a global leader in biosimilar development, with a strong presence in India. The company focuses on oncology and immunology biosimilars.
2. Eli Lilly and Company
Eli Lilly is renowned for its insulin biosimilars, addressing the growing diabetes burden in India.
3. Celltrion Healthcare
Celltrion offers a diverse biosimilar portfolio, including monoclonal antibodies for cancer and autoimmune diseases.
(FAQs)
1. What is the current size of the India biosimilar market?
The market was valued at INR 2.20 billion in 2023.
2. What factors are driving the biosimilar market in India?
Rising prevalence of chronic diseases, cost-effective production, and government support are key drivers.
3. Which therapeutic areas dominate the biosimilar market?
Oncology, autoimmune diseases, and diabetes are major therapeutic areas.
4. What is the expected growth rate of the market?
The market is projected to grow at a CAGR of 25.20% during 2025-2034.
5. How has COVID-19 impacted the biosimilar market?
The pandemic accelerated investments in biosimilar R&D and adoption of digital tools for development.
Media Contact:
Company Name: Claight Corporation
Contact Person: Dhruv, Corporate Sales Specialist — U.S.A.
Email: sales@expertmarketresearch.com
Toll Free Number: +1–415–325–5166 | +44–702–402–5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
Aus Site: https://www.expertmarketresearch.com.au
